Collaborative Arrangement milestone payment amount.

No definition available.

Name:	plx_CollaborativeArrangementMilestonePaymentAmount
Namespace Prefix:	plx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Collaborative arrangement profit sharing percentage.

+ References

No definition available.

+ Details

Name:	plx_CollaborativeArrangementProfitSharePercentage
Namespace Prefix:	plx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

License And Supply Agreement Potential Future Payment Based On Net Profits

+ References

No definition available.

+ Details

Name:	plx_LicenseAndSupplyAgreementPotentialFuturePaymentBasedOnNetProfits
Namespace Prefix:	plx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of subsidiaries.

+ References

No definition available.

+ Details

Name:	plx_NumberOfSubsidiaries
Namespace Prefix:	plx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The floor purchase amount that one or more customers of the entity must satisfy in order to be entitled to certain rights under the terms of disclosed arrangements.

+ References

No definition available.

+ Details

Name:	plx_PurchaseAmountToBeSatisfiedToReceiveEntitledRights
Namespace Prefix:	plx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	plx_SignificantAccountingPoliciesLineItems
Namespace Prefix:	plx_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The floor purchase amount that one or more customers of the entity must satisfy per calendar year to comply with the terms of disclosed arrangements.

+ References

No definition available.

+ Details

Name:	plx_SupplyCommitmentPerYear
Namespace Prefix:	plx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

+ Details

Name:	us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name:	us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix:	us-gaap_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Cash received from collaborators during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromCollaborators
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	dei_LegalEntityAxis=us-gaap_SubsidiariesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementScenarioAxis=plx_UponFDAApprovalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=plx_PfizerIncorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=plx_ProtalixBioTherapeuticsIncorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	3 Months Ended	12 Months Ended			1 Months Ended
SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	Dec. 31, 2009	Dec. 31, 2014 item	Dec. 31, 2013	Dec. 31, 2012	Jun. 18, 2013
Significant Accounting Policies [Line Items]
Number of Subsidiaries		2plx_NumberOfSubsidiaries
Pfizer Agreement, upfront payment received	$ 60,000,000us-gaap_ProceedsFromCollaborators
Common stock, par value per share		$ 0.001	$ 0.001
Options to purchase common stock not included in diluted LPS because the effect would be anti-dilutive		18,850,724	10,675,304	7,280,469
Revenues		13,651,000us-gaap_Revenues	10,479,000us-gaap_Revenues	34,870,000us-gaap_Revenues
Protalix Ltd. [Member]
Significant Accounting Policies [Line Items]
Supply commitment for entitled rights to be received					280,000,000
License and supply agreement potential future payment					12,500,000
Supply commitment per year					40,000,000
Protalix Ltd. [Member] \| Revenues from sale of products [Member]
Significant Accounting Policies [Line Items]
Revenues		3,500,000
Protalix Bio Therapeutics Inc. [Member]
Significant Accounting Policies [Line Items]
Pfizer Agreement, future revenues and expense sharing percentage		40.00%
Pfizer Incorporation [Member]
Significant Accounting Policies [Line Items]
Pfizer Agreement, future revenues and expense sharing percentage		60.00%
Upon FDAApproval [Member]
Significant Accounting Policies [Line Items]
Pfizer Agreement, milestone payment amount		$ 30,000,000